These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


116 related items for PubMed ID: 20692812

  • 1. Third degree heart block following intramuscular ziprasidone.
    Tambyraja R, Strawn JR.
    Schizophr Res; 2011 Feb; 125(2-3):302-3. PubMed ID: 20692812
    [No Abstract] [Full Text] [Related]

  • 2. Inadvertent administration of intravenous ziprasidone leading to bradycardia and QT interval prolongation.
    Bentley ML, Biscardi FH, Butcher C, Levitov A.
    Ann Pharmacother; 2008 Jun; 42(6):902-3. PubMed ID: 18477728
    [No Abstract] [Full Text] [Related]

  • 3. Parkinsonism with intramuscular ziprasidone.
    Bilal L, Tsai C, Gasper JJ, Ndlela JC.
    Am J Psychiatry; 2005 Dec; 162(12):2392-3. PubMed ID: 16330610
    [No Abstract] [Full Text] [Related]

  • 4. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia.
    Ziegenbein M, Calliess IT.
    J Neuropsychiatry Clin Neurosci; 2006 Dec; 18(2):246-7. PubMed ID: 16720806
    [No Abstract] [Full Text] [Related]

  • 5. Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone.
    Yeh YW, Chen YC, Chen CK, Feng HM, Wang TY, Chen CL.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb 01; 33(1):162-3. PubMed ID: 19028541
    [No Abstract] [Full Text] [Related]

  • 6. Transient, asymptomatic, fluctuating bradycardia with oral ziprasidone in an older woman.
    Menon V, Ramamourthy P, Ayyanar S.
    Aust N Z J Psychiatry; 2014 Feb 01; 48(2):201-2. PubMed ID: 23934959
    [No Abstract] [Full Text] [Related]

  • 7. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.
    Greco KE, Tune LE, Brown FW, Van Horn WA.
    J Clin Psychiatry; 2005 Jul 01; 66(7):928-9. PubMed ID: 16013910
    [Abstract] [Full Text] [Related]

  • 8. [Risk of QTc prolongation due to combination of ziprasidone and quetiapine].
    Minov C.
    Psychiatr Prax; 2004 Nov 01; 31 Suppl 1():S142-4. PubMed ID: 15570533
    [Abstract] [Full Text] [Related]

  • 9. Ziprasidone-induced acute dystonia.
    Mason MN, Johnson CE, Piasecki M.
    Am J Psychiatry; 2005 Mar 01; 162(3):625-6. PubMed ID: 15741487
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Ziprasidone-augmentation of clozapine].
    Zink M, Mase E, Dressing H.
    Psychiatr Prax; 2004 Jul 01; 31(5):259-61. PubMed ID: 15243877
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Question regarding ziprasidone and QTc interval prolongation in the ZODIAC study.
    Vieweg WV, Hasnain M.
    Am J Psychiatry; 2011 Jun 01; 168(6):650-1; author reply 651. PubMed ID: 21642483
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Practical aspects of the use of ziprasidone in schizophrenia].
    Ochedzan D, Jarema M.
    Psychiatr Pol; 2010 Jun 01; 44(6):881-93. PubMed ID: 21449170
    [Abstract] [Full Text] [Related]

  • 17. Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.
    Lee CP, Chen AP, Juang YY.
    Clin Schizophr Relat Psychoses; 2015 Jun 01; 9(3):141-4. PubMed ID: 23644168
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
    Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, Buckley P, Manschreck TC, Achtyes ED, Macklin EA.
    J Clin Psychopharmacol; 2013 Aug 01; 33(4):485-90. PubMed ID: 23775057
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.